445 related articles for article (PubMed ID: 29402900)
1. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH.
Shiba K; Tsuchiya K; Komiya C; Miyachi Y; Mori K; Shimazu N; Yamaguchi S; Ogasawara N; Katoh M; Itoh M; Suganami T; Ogawa Y
Sci Rep; 2018 Feb; 8(1):2362. PubMed ID: 29402900
[TBL] [Abstract][Full Text] [Related]
2. The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma.
Jojima T; Wakamatsu S; Kase M; Iijima T; Maejima Y; Shimomura K; Kogai T; Tomaru T; Usui I; Aso Y
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31652578
[TBL] [Abstract][Full Text] [Related]
3. Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
Woods TC; Satou R; Miyata K; Katsurada A; Dugas CM; Klingenberg NC; Fonseca VA; Navar LG
Am J Nephrol; 2019; 49(4):331-342. PubMed ID: 30921791
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.
Yamada T; Kashiwagi Y; Rokugawa T; Kato H; Konishi H; Hamada T; Nagai R; Masago Y; Itoh M; Suganami T; Ogawa Y; Abe K
Magn Reson Imaging; 2019 Apr; 57():210-217. PubMed ID: 30465867
[TBL] [Abstract][Full Text] [Related]
5. Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
Komiya C; Tanaka M; Tsuchiya K; Shimazu N; Mori K; Furuke S; Miyachi Y; Shiba K; Yamaguchi S; Ikeda K; Ochi K; Nakabayashi K; Hata KI; Itoh M; Suganami T; Ogawa Y
Sci Rep; 2017 Mar; 7():44754. PubMed ID: 28303974
[TBL] [Abstract][Full Text] [Related]
6. Myeloid-specific IRE1alpha deletion reduces tumour development in a diabetic, non-alcoholic steatohepatitis-induced hepatocellular carcinoma mouse model.
Van Campenhout S; Tilleman L; Lefere S; Vandierendonck A; Raevens S; Verhelst X; Geerts A; Van Nieuwerburgh F; Van Vlierberghe H; Devisscher L
Metabolism; 2020 Jun; 107():154220. PubMed ID: 32243868
[TBL] [Abstract][Full Text] [Related]
7. Eicosapentaenoic acid ameliorates non-alcoholic steatohepatitis in a novel mouse model using melanocortin 4 receptor-deficient mice.
Konuma K; Itoh M; Suganami T; Kanai S; Nakagawa N; Sakai T; Kawano H; Hara M; Kojima S; Izumi Y; Ogawa Y
PLoS One; 2015; 10(3):e0121528. PubMed ID: 25816330
[TBL] [Abstract][Full Text] [Related]
8. Melanocortin 4 receptor-deficient mice as a novel mouse model of nonalcoholic steatohepatitis.
Itoh M; Suganami T; Nakagawa N; Tanaka M; Yamamoto Y; Kamei Y; Terai S; Sakaida I; Ogawa Y
Am J Pathol; 2011 Nov; 179(5):2454-63. PubMed ID: 21906580
[TBL] [Abstract][Full Text] [Related]
9. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis-associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects.
Kawakubo M; Tanaka M; Ochi K; Watanabe A; Saka-Tanaka M; Kanamori Y; Yoshioka N; Yamashita S; Goto M; Itoh M; Shirakawa I; Kanai S; Suzuki H; Sawada M; Ito A; Ishigami M; Fujishiro M; Arima H; Ogawa Y; Suganami T
Sci Rep; 2020 Jan; 10(1):983. PubMed ID: 31969650
[TBL] [Abstract][Full Text] [Related]
10. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model.
Yoshioka N; Tanaka M; Ochi K; Watanabe A; Ono K; Sawada M; Ogi T; Itoh M; Ito A; Shiraki Y; Enomoto A; Ishigami M; Fujishiro M; Ogawa Y; Suganami T
Biomed Pharmacother; 2021 Aug; 140():111738. PubMed ID: 34029949
[TBL] [Abstract][Full Text] [Related]
11. Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis.
Goto T; Itoh M; Suganami T; Kanai S; Shirakawa I; Sakai T; Asakawa M; Yoneyama T; Kai T; Ogawa Y
Sci Rep; 2018 May; 8(1):8157. PubMed ID: 29802399
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of sodium glucose cotransporter 2 (SGLT2) delays liver fibrosis in a medaka model of nonalcoholic steatohepatitis (NASH).
Goto R; Kamimura K; Shinagawa-Kobayashi Y; Sakai N; Nagoya T; Niwa Y; Ko M; Ogawa K; Inoue R; Yokoo T; Sakamaki A; Kamimura H; Abe S; Nishina H; Terai S
FEBS Open Bio; 2019 Apr; 9(4):643-652. PubMed ID: 30984539
[TBL] [Abstract][Full Text] [Related]
13. Sodium glucose cotransporter 2 inhibitor canagliflozin attenuates liver cancer cell growth and angiogenic activity by inhibiting glucose uptake.
Kaji K; Nishimura N; Seki K; Sato S; Saikawa S; Nakanishi K; Furukawa M; Kawaratani H; Kitade M; Moriya K; Namisaki T; Yoshiji H
Int J Cancer; 2018 Apr; 142(8):1712-1722. PubMed ID: 29205334
[TBL] [Abstract][Full Text] [Related]
14. Canagliflozin ameliorates hepatic fat deposition in obese diabetic mice: Role of prostaglandin E
Yoshino K; Hosooka T; Shinohara M; Aoki C; Hosokawa Y; Imamori M; Ogawa W
Biochem Biophys Res Commun; 2021 Jun; 557():62-68. PubMed ID: 33862461
[TBL] [Abstract][Full Text] [Related]
15. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Tahara A; Takasu T
Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice.
Tahara A; Takasu T
Endocr Res; 2020; 45(2):147-161. PubMed ID: 31955626
[No Abstract] [Full Text] [Related]
17. Curcumin ameliorates liver damage and progression of NASH in NASH-HCC mouse model possibly by modulating HMGB1-NF-κB translocation.
Afrin R; Arumugam S; Rahman A; Wahed MI; Karuppagounder V; Harima M; Suzuki H; Miyashita S; Suzuki K; Yoneyama H; Ueno K; Watanabe K
Int Immunopharmacol; 2017 Mar; 44():174-182. PubMed ID: 28110063
[TBL] [Abstract][Full Text] [Related]
18. The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice.
Honda Y; Imajo K; Kato T; Kessoku T; Ogawa Y; Tomeno W; Kato S; Mawatari H; Fujita K; Yoneda M; Saito S; Nakajima A
PLoS One; 2016; 11(1):e0146337. PubMed ID: 26731267
[TBL] [Abstract][Full Text] [Related]
19. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma.
Du D; Liu C; Qin M; Zhang X; Xi T; Yuan S; Hao H; Xiong J
Acta Pharm Sin B; 2022 Feb; 12(2):558-580. PubMed ID: 35256934
[TBL] [Abstract][Full Text] [Related]
20. Combined Treatment with Sodium-Glucose Cotransporter-2 Inhibitor (Canagliflozin) and Dipeptidyl Peptidase-4 Inhibitor (Teneligliptin) Alleviates NASH Progression in A Non-Diabetic Rat Model of Steatohepatitis.
Ozutsumi T; Namisaki T; Shimozato N; Kaji K; Tsuji Y; Kaya D; Fujinaga Y; Furukawa M; Nakanishi K; Sato S; Sawada Y; Saikawa S; Kitagawa K; Takaya H; Kawaratani H; Kitade M; Moriya K; Noguchi R; Akahane T; Mitoro A; Yoshiji H
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
